Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21).
- Author:
Yang-Li HAN
1
;
Su-Jiang ZHANG
;
Chun QIAO
;
Dan DAI
;
Xue-Mei SUN
;
Yan-Li XU
;
Si-Xuan QIAN
;
Wei XU
;
Ji-Shi WANG
;
Jian-Yong LI
Author Information
1. Department of Hematology, The First Hospital, Nanjing Medical University, Jiangsu Provincial People Hospital, Nanjing 210029, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
Female;
Humans;
Janus Kinase 2;
genetics;
Leukemia, Myeloid, Acute;
genetics;
Male;
Middle Aged;
Mutation;
Proto-Oncogene Proteins c-kit;
genetics;
Tandem Repeat Sequences;
Young Adult;
fms-Like Tyrosine Kinase 3;
genetics
- From:
Journal of Experimental Hematology
2009;17(4):866-869
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the status of c-KIT, Fms-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2) mutations in acute myeloid leukemia (AML) patients with t (8; 21) and to analyze their relation to clinical feature and prognosis. PCR, AS-PCR, restriction and sequencing methods were used respectively to detect the FLT3, JAK 2 and c-KIT mutations in 8 cases of de novo AML with t (8; 21) and 6 cases of relapsed AML with t (8; 21). The results showed that the c-KIT mutation was found in 2 cases out of 14 AML patients with t (8; 21) (14.3%), among them 1 case had c-KIT D816V mutation, the other had c-KIT D816Y mutation. The FLT3-ITD mutation was detect in 1 out of 14 patients (7.1%), but JAK2 mutation could not be detected in all 14 cases. In conclusion, tyrosine kinase mutation relates to AML with t (8; 21), patients with tyrosine kinase mutation may have higher relapse, extramedullary infiltration and poor prognosis. The screening c-KIT, FLT3 mutations may play an important role in evaluating prognosis and guiding treatment of t (8; 21) AML.
